Multiple Myeloma APAC Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Cartesian Therapeutics, Alliance Foundation Trials, US Oncology Research, SCRI Development Innovations, Celgene, Sorrento Therapeuti

DelveInsight's "Multiple Myeloma Patient Pool Analysis, Market Size and Market Forecast APAC - 2034″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast
https://www.delveinsight.com/sample-request/multiple-myeloma-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Multiple Myeloma Market Report:
• The APAC Multiple Myeloma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Key Multiple Myeloma Companies: Cartesian Therapeutics, Alliance Foundation Trials, US Oncology Research, SCRI Development Innovations, Celgene, Sorrento Therapeutics, Inc., iTeos Belgium SA, Pfizer, AstraZeneca, Ascentage Pharma Group Inc., TeneoOne Inc., Hoffmann-La Roche, Bristol-Myers Squibb, Novartis, Gilead Sciences, and others
• Key Multiple Myeloma Therapies: Descartes 08, Lenalidomide, Selinexor, Teclistamab, bb2121, STI-6129, EOS884448, Elranatamab, AZD0305, APG-2575, TNB-383B, Cevostamab, Iberdomide, PHE885, Magrolimab, and others
• In December 2022, Kite, a subsidiary of Gilead, has forged a global strategic alliance with Arcellx for the collaborative advancement and commercialization of CART-ddBCMA, a T-cell therapy designed for individuals with relapsed or refractory multiple myeloma. The CART-ddBCMA is presently undergoing Phase I clinical investigation. As part of this collaboration, Arcellx is set to provide an initial payment of USD 225 million to Kite.
• In October 2022, The FDA has expedited approval for teclistamab-cqyv, a pioneering bispecific B-cell maturation antigen (BCMA)-targeted CD3 T-cell engager developed by Janssen Biotech. This approval is designated for adult patients experiencing relapsed or refractory multiple myeloma.
• The Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

Multiple Myeloma Overview
Multiple Myeloma is a type of cancer that originates in plasma cells, a type of white blood cell responsible for producing antibodies to help the immune system fight infections. In Multiple Myeloma, malignant plasma cells grow uncontrollably in the bone marrow, crowding out healthy blood cells.

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/multiple-myeloma-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Multiple Myeloma Epidemiology Segmentation:
The Multiple Myeloma market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:
• Total Prevalence of Multiple Myeloma
• Prevalent Cases of Multiple Myeloma by severity
• Gender-specific Prevalence of Multiple Myeloma
• Diagnosed Cases of Episodic and Chronic Multiple Myeloma
Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast
https://www.delveinsight.com/sample-request/multiple-myeloma-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Multiple Myeloma Therapies and Key Companies
• Descartes 08: Cartesian Therapeutics
• Lenalidomide: Alliance Foundation Trials
• Selinexor: US Oncology Research
• Teclistamab: SCRI Development Innovations
• bb2121: Celgene
• STI-6129: Sorrento Therapeutics, Inc.
• EOS884448: iTeos Belgium SA
• Elranatamab: Pfizer
• AZD0305: AstraZeneca
• APG-2575: Ascentage Pharma Group Inc.
• TNB-383B: TeneoOne Inc.
• Cevostamab: Hoffmann-La Roche
• Iberdomide: Bristol-Myers Squibb
• PHE885: Novartis
• Magrolimab: Gilead Sciences
Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape
https://www.delveinsight.com/sample-request/multiple-myeloma-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Multiple Myeloma Market Report
• Study Period: 2020-2034
• Coverage: APAC (India, China, South Korea, Taiwan, and Australia)
• Key Multiple Myeloma Companies: Cartesian Therapeutics, Alliance Foundation Trials, US Oncology Research, SCRI Development Innovations, Celgene, Sorrento Therapeutics, Inc., iTeos Belgium SA, Pfizer, AstraZeneca, Ascentage Pharma Group Inc., TeneoOne Inc., Hoffmann-La Roche, Bristol-Myers Squibb, Novartis, Gilead Sciences, and others
• Key Multiple Myeloma Therapies: Descartes 08, Lenalidomide, Selinexor, Teclistamab, bb2121, STI-6129, EOS884448, Elranatamab, AZD0305, APG-2575, TNB-383B, Cevostamab, Iberdomide, PHE885, Magrolimab, and others
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Multiple Myeloma Unmet Needs, KOL's views, Analyst's views, Multiple Myeloma Market Access and Reimbursement

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/multiple-myeloma-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Multiple Myeloma Market Report Introduction
2. Executive Summary for Multiple Myeloma
3. SWOT analysis of Multiple Myeloma
4. Multiple Myeloma Patient Share (%) Overview at a Glance
5. Multiple Myeloma Market Overview at a Glance
6. Multiple Myeloma Disease Background and Overview
7. Multiple Myeloma Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple Myeloma
9. Multiple Myeloma Current Treatment and Medical Practices
10. Multiple Myeloma Unmet Needs
11. Multiple Myeloma Emerging Therapies
12. Multiple Myeloma Market Outlook
13. Country-Wise Multiple Myeloma Market Analysis (2020-2034)
14. Multiple Myeloma Market Access and Reimbursement of Therapies
15. Multiple Myeloma Market Drivers
16. Multiple Myeloma Market Barriers
17. Multiple Myeloma Appendix
18. Multiple Myeloma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports by DelveInsight
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.